In the pandemic age of telehealth and new technologies, remote site lab or point-of-care (POC) testing of biofluids is a potentially rapid and non-invasive way to test for most diseases – including COVID-19.Now scientists at Flinders University have run tests on the bioprobe industry, recommending the potential of a novel group of bioprobes with aggregation-induced emission (AIE) properties, so-called AIEgens, as being the best way forward to deliver accurate clinical biomarkers.
- Soil-powered fuel cell promises cheap, sustainable water purification
- Reforestation plans in Africa could go awry
- Coral researchers find link between bacterial genus and disease susceptibility
- How computer scientists and marketers can create a better CX with AI
- Scientists discover new organic compounds that could have helped form the first cells